Pyxis Oncology director exercises options, sells shares
Pyxis Oncology director Jakob Dupont reported an exercise-and-sale of company stock.
Rhea-AI Filing Summary
Pyxis Oncology director Jakob Dupont reported an exercise-and-sale of company stock. He exercised stock options covering 35,000 shares of common stock at an exercise price of $1.60 per share and received the underlying shares.
On the same date, he sold 35,000 common shares in open-market transactions at a weighted average price of $3.06 per share, with trade prices ranging from $3.00 to $3.36. These sales were carried out under a pre-arranged Rule 10b5-1 trading plan. After the transactions, Dupont holds 38,741 shares of Pyxis Oncology common stock directly.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 35,000 shares ($51K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Dupont Jakob
Role
Director
Sold
35,000 shs ($107K)
Approx. gross sale proceeds
$107K
Approx. exercise cost
$56K
Approx. pre-tax spread
$51K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 35,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 35,000 | $1.60 | $56K |
| Sale | Common Stock | 35,000 | $3.06 | $107K |
Holdings After Transaction:
Stock Option (Right to Buy) — 357,461 contracts (Direct);
Common Stock — 38,741 shares (Direct)
Footnotes (4)
- F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on Septemeber 24, 2025.
- F2. Reflects sales of common stock executed in multiple transactions. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected within the ranges set forth in footnotes 3 of this Form 4.
- F3. The transaction was executed in multiple trades in prices ranging from $3.00 to $3.36.
- F4. Award of stock options to purchase Common Shares with a vesting commencement date of August 23, 2024. These options vest and become exercisable in three equal annual tranches from August 23, 2023, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).
Key Figures
Shares sold: 35,000 shares
Weighted average sale price: $3.06 per share
Shares acquired via option exercise: 35,000 shares
+4 more
7 metrics
Shares sold
35,000 shares
Common stock sold in open market on June 30, 2026
Weighted average sale price
$3.06 per share
Common stock sale, trades between $3.00 and $3.36
Shares acquired via option exercise
35,000 shares
Common stock received from stock option exercise
Option exercise price
$1.60 per share
Stock Option (Right to Buy) underlying common stock
Shares held after transactions
38,741 shares
Direct common stock ownership following June 30, 2026 trades
Option expiration date
September 22, 2033
Expiration of Stock Option (Right to Buy)
Sale price range
$3.00–$3.36 per share
Range of prices for multiple sale transactions
Key Terms
Rule 10b5-1 trading plan, weighted average sale price, Stock Option (Right to Buy), vesting commencement date, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"The price reported reflects the weighted average sale price."
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
vesting commencement date financial
"Award of stock options to purchase Common Shares with a vesting commencement date of August 23, 2024."
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Pyxis Oncology (PYXS) director Jakob Dupont report in this Form 4?
Director Jakob Dupont reported exercising stock options for 35,000 Pyxis Oncology shares at $1.60 and selling 35,000 shares at a weighted average price of $3.06. Following these transactions, he directly owns 38,741 shares of Pyxis Oncology common stock.
What option exercise did Jakob Dupont report for Pyxis Oncology (PYXS)?
He exercised stock options to acquire 35,000 shares of Pyxis Oncology common stock at an exercise price of $1.60 per share. The related derivative entry shows a stock option to buy 35,000 shares with an expiration date of September 22, 2033.
AI-generated analysis. How Rhea-AI works. Not financial advice.
